DVAX vs. LGND, GERN, PRTA, IRWD, MNKD, OPK, INVA, LXRX, MRNS, and URGN
Should you be buying Dynavax Technologies stock or one of its competitors? The main competitors of Dynavax Technologies include Ligand Pharmaceuticals (LGND), Geron (GERN), Prothena (PRTA), Ironwood Pharmaceuticals (IRWD), MannKind (MNKD), OPKO Health (OPK), Innoviva (INVA), Lexicon Pharmaceuticals (LXRX), Marinus Pharmaceuticals (MRNS), and UroGen Pharma (URGN). These companies are all part of the "medical" sector.
Ligand Pharmaceuticals (NASDAQ:LGND) and Dynavax Technologies (NASDAQ:DVAX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability, community ranking and analyst recommendations.
Ligand Pharmaceuticals presently has a consensus target price of $116.33, suggesting a potential upside of 47.50%. Dynavax Technologies has a consensus target price of $25.00, suggesting a potential upside of 118.72%. Given Ligand Pharmaceuticals' higher possible upside, analysts clearly believe Dynavax Technologies is more favorable than Ligand Pharmaceuticals.
Ligand Pharmaceuticals has higher earnings, but lower revenue than Dynavax Technologies. Dynavax Technologies is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Ligand Pharmaceuticals received 65 more outperform votes than Dynavax Technologies when rated by MarketBeat users. Likewise, 69.92% of users gave Ligand Pharmaceuticals an outperform vote while only 65.86% of users gave Dynavax Technologies an outperform vote.
In the previous week, Ligand Pharmaceuticals had 3 more articles in the media than Dynavax Technologies. MarketBeat recorded 5 mentions for Ligand Pharmaceuticals and 2 mentions for Dynavax Technologies. Ligand Pharmaceuticals' average media sentiment score of 1.67 beat Dynavax Technologies' score of 1.17 indicating that Dynavax Technologies is being referred to more favorably in the news media.
91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 97.0% of Dynavax Technologies shares are held by institutional investors. 10.4% of Ligand Pharmaceuticals shares are held by insiders. Comparatively, 9.3% of Dynavax Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Ligand Pharmaceuticals has a net margin of 37.80% compared to Ligand Pharmaceuticals' net margin of -2.75%. Dynavax Technologies' return on equity of 11.98% beat Ligand Pharmaceuticals' return on equity.
Ligand Pharmaceuticals has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, Dynavax Technologies has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.
Summary
Ligand Pharmaceuticals beats Dynavax Technologies on 12 of the 17 factors compared between the two stocks.
Get Dynavax Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for DVAX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dynavax Technologies Competitors List
Related Companies and Tools
